Cerebral white matter changes and rate of progression of dementia during cholinesterase inhibitor treatment: A retrospective cohort study

International Journal of Geriatric Psychiatry

Volumn 22, Issue 11, 2007, Pages 1120-1126

  Devine, Mike E ^a   Fonseca, J A S ^b   Walker, R W H ^c   Sikdar, T ^d   Stevens, T ^b   Walker, Z ^e  

^a NORTH EAST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b St Margaret's Hospital   (United Kingdom)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

^d PRINCESS ALEXANDRA HOSPITAL   (United Kingdom)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cerebrovascular disorders; Cholinesterase inhibitors; Dementia; Disease progression; Treatment outcome

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PROGNOSIS; TREATMENT DURATION; WHITE MATTER;

EID: 36248990722     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1799     Document Type: Article

References (22)

1. Aarsland D, Mosimann UP, McKeith IG. 2004. Role of cholinesterase inhibitors in Parkinson's Disease and Dementia with Lewy Bodies. J Geriatr Psychiatry Neurol 17: 164-171.
2. Bowler JV. 2003. Acetylcholinesterase inhibitors for Vascular Dementia and Alzheimer's disease combined with cerebrovascular disease. Stroke 34: 584-586.
3. Bullock R. 2004. Cholinesterase inhibitors and vascular dementia: another string to their bow? CNS Drugs 18: 79-92.
4. Connelly PJ, Prentice NP, Fowler KG. 2005. Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease. Int J Geriatr Psychiatry 20: 623-628.
5. Erkinjuntti T, Román G, Gauthier S. 2004. Treatment of vascular dementia - evidence from clinical trials with cholinesterase inhibitors. J Neurol Sci 226: 63-66.
6. Folstein MF, Folstein SE, McHugh PA. 1975. 'Mini Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
7. Holmes C, Ballard C, Lehmann D, et al. 2005. Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. J Neural Neurosurg Psychiatry 76: 640-643.
8. Lawton MP, Brody EM. 1969. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9: 179-186.
9. McKeith IG, Del Ser T, Spano PF, et al. 2000. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356: 2031-2036.
10. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). 2001. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357: 169-175.
11. Pasquier F, Richard F, Lebert F. 2004. Natural history of frontotemporal dementia: comparison with Alzheimer's disease. Dement Geriatr Cogn Disord 17: 253-257.
12. Pattie AH, Gilleard CJ. 1979. Manual of the Clifton Assessment Procedures for the Elderly (CAPE). Hodder & Stoughton: Sevenoaks, Kent.
13. Perry EK, Irving D, Kerwin JM, et al. 1993. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 7: 69-79.
14. Perry E, Ziabreva I, Perry R, et al. 2005. Absence of cholinergic deficits in pure vascular dementia. Neurology 64: 132-133.
15. Román GC. 2005. Cholinergic dysfunction in vascular dementia. Curr Psychiatry Rep 7: 18-26.
16. Rosen WG, Terry RD, Fuld PA, et al. 1980. Pathological verification of ischaemic score in differentiation of dementias. Ann Neurol 7: 480488.
17. Roth M, Tym E, Mounqoy CQ, et al. 1986. CAMDEX a standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149: 698-709.
18. Salmon DP, Thal U, Butters N, et al. 1990. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology 40: 1225-1230.
19. Schoenmaker N, Van Gool WA. 2004. Tle age gap between patients in clinical studies and in the general population: a pitfall for dementia research. Lancet Neurol 3: 627-630.
20. Sub GH, Ju YS, Yeon BK, et al. 2004. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. Int J Geriatr Psychiatry 19: 817-824.
21. Tiraboschi P, Hansen LA, Alford M, et al. 2000. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 54: 407-411.
22. Wahlund LO, Barkhof F, Fazekas F, et al. 2001. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32: 1318-1322.